Kezar Life Sciences was forced to close after an FDA delay in scheduling a critical meeting for its clinical trial, highlighting the impact of regulatory delays on biotech startups. This underscores the importance of timely communication between regulators and developers for the survival of small biotechs. Developers should watch for further instances where regulatory timelines affect drug development progress.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



